文献速递胸部肿瘤放疗放疗物理与技术

同步贝伐珠单抗与胸部放疗患者放射性肺炎的发生率及危险因素

The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy.
PubMed 文献 · Radiat Oncol · 2024-05-30

该研究回顾性分析了2017至2020年山东省肿瘤医院119例一线化疗联合贝伐珠单抗期间接受胸部放疗的NSCLC患者病历,≥2级放射性肺炎发生率为31.9%,男性、V20>16.9%和PTV体积>183.85 cm³为独立预测因素。

要点

  • 119例患者中≥2级放射性肺炎发生率为31.9%,其中2级占68.1%,3级占9.2%,无4级或5级。
  • 多因素分析显示男性、V20>16.9%和PTV体积>183.85 cm³是放射性肺炎的独立预测因素。
  • 全组中位无进展生存期为14.27个月(95%CI 13.1-16.1),中位总生存期为37.09个月(95%CI 33.8-42.0)。

核心结论

  • 接受贝伐珠单抗联合胸部放疗的NSCLC患者≥2级放射性肺炎发生率为31.9%。
  • 限制V20和PTV等因素有助于降低此类患者放射性肺炎风险。
  • 作者认为,对同时接受贝伐珠单抗和胸部放疗的患者,增加胸部放疗时应谨慎,并应优化治疗策略以降低放射性肺炎发生率。

研究设计与样本

  • 回顾性研究,通过机构查询系统审查2017至2020年山东省肿瘤医院119例一线化疗联合贝伐珠单抗期间接受胸部放疗的NSCLC患者病历。
  • 放射性肺炎经计算机断层扫描诊断,并按RTOG毒性评分系统分级。
  • 采用单因素和多因素分析识别放射性肺炎危险因素,Kaplan-Meier法计算无进展生存期和总生存期。

主要发现

  • 119例患者中38例(31.9%)发生≥2级放射性肺炎,其中27例(68.1%)为2级,11例(9.2%)为3级,无4级或5级放射性肺炎。
  • 放射性肺炎发生的中位时间为2.7个月(范围1.2-5.4个月)。
  • 单因素分析中,男性、年龄、KPS评分、V20>16.9%、V5>33.6%、PTV剂量>57.2 Gy和PTV体积>183.85 cm³与放射性肺炎发生相关。
  • 多因素分析中,男性、V20>16.9%和PTV体积>183.85 cm³被确定为放射性肺炎发生的独立预测因素。
  • 全组中位无进展生存期为14.27个月(95%CI 13.1-16.1),1年和2年无进展生存率分别为64.9%和20.1%;中位总生存期为37.09个月(95%CI 33.8-42.0),1年和2年生存率分别为95%和71.4%。

关键数值与推荐

  • ≥2级放射性肺炎发生率为31.9%(38/119),其中2级占68.1%(27/38),3级占9.2%(11/119)。
  • 多因素分析独立预测因素:男性、V20>16.9%、PTV体积>183.85 cm³。
  • 放射性肺炎发生中位时间2.7个月(范围1.2-5.4个月)。
  • 全组中位无进展生存期14.27个月(95%CI 13.1-16.1),中位总生存期37.09个月(95%CI 33.8-42.0)。

临床怎么用

  • 作者认为,限制V20和PTV等因素有助于降低接受贝伐珠单抗联合胸部放疗患者的放射性肺炎风险。
  • 作者认为,对同时接受贝伐珠单抗和胸部放疗的患者,增加胸部放疗时应谨慎,并应优化治疗策略以降低放射性肺炎发生率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: First-line chemotherapy combined with bevacizumab is one of the standard treatment modes for patients with advanced non-small cell lung cancer (NSCLC). Thoracic radiotherapy (TRT) can provide significant local control and survival benefits to patients during the treatment of advanced NSCLC. However, the safety of adding TRT has always been controversial, especially because of the occurrence of radiation pneumonia (RP) during bevacizumab treatment. Therefore, in this study, we used an expanded sample size to evaluate the incidence of RP when using bevacizumab in combination with TRT. PATIENTS AND METHODS: Using an institutional query system, all medical records of patients with NSCLC who received TRT during first-line chemotherapy combined with bevacizumab from 2017 to 2020 at Shandong Cancer Hospital and Institute were reviewed. RP was diagnosed via computed tomography and was classified according to the RTOG toxicity scoring system. The risk factors for RP were identified using univariate and multivariate analyses. The Kaplan-Meier method was used to calculate progression-free survival (PFS) and overall survival (OS). RESULTS: Ultimately, 119 patients were included. Thirty-eight (31.9%) patients developed Grade ≥ 2 RP, of whom 27 (68.1%) had Grade 2 RP and 11 (9.2%) had Grade 3 RP. No patients developed Grade 4 or 5 RP. The median time for RP occurrence was 2.7 months (range 1.2-5.4 months). In univariate analysis, male, age, KPS score, V20 > 16.9%, V5 > 33.6%, PTV (planning target volume)-dose > 57.2 Gy, and PTV-volume > 183.85 cm3 were correlated with the occurrence of RP. In multivariate analysis, male, V20 > 16.9%, and PTV-volume > 183.85 cm3 were identified as independent predictors of RP occurrence. The mPFS of all patients was 14.27 (95% CI, 13.1-16.1) months. The one-year and two-year PFS rates were 64.9% and 20.1%, respectively. The mOS of all patients was 37.09 (95% CI, 33.8-42.0) months. The one-year survival rate of all patients was 95%, and the two-year survival rate was 71.4%. CONCLUSIONS: The incidence of Grade ≥ 2 RP in NSCLC patients who received both bevacizumab and TRT was 31.9%. Restricting factors such as V20 and PTV will help reduce the risk of RP in these patients. For patients who receive both bevacizumab and TRT, caution should be exercised when increasing TRT, and treatment strategies should be optimized to reduce the incidence of RP.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen F, Niu J, Wang M, et al. The incidence of and risk factors for radiation pneumonitis in patients treated with simultaneous bevacizumab and thoracic radiotherapy. Radiat Oncol. 2024. PMID: 38816745. doi:10.1186/s13014-024-02458-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。